$CNC

Burdick Kenneth A sold $5.2M of CNC

Burdick Kenneth A sold 80,000 shares of CENTENE CORP (CNC) at $64.55 ($5.16M total) on 2026-06-10.

Original reporting
SEC EDGAR · Burdick Kenneth A
Published Jun 11, 2026, 9:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CNC
Bearish
medium confidence
Mentioned
$CNC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CNCBearishLow
01

Why it matters

The only new information is the disclosed sale size, price, and post-transaction holdings; it may slightly affect sentiment but lacks fundamental triggers.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a sustained repricing.

03

What to watch

No 10b5-1 plan is stated, but the filing alone cannot distinguish discretionary selling from scheduled personal liquidity needs; traders should check for repeated insider activity around the same period.

Relevance 6/10Novelty 6/10Timing: New SEC Form 4 filed June 11; sale executed June 10

Background

The article is an SEC Form 4 insider transaction disclosure for Centene’s director Kenneth A. Burdick.

Company-level read

Ticker impact

$CNCBearishMedium confidence
Context

Centene director Kenneth A. Burdick sold 80,000 shares in an open-market transaction worth about $5.164M, per a new SEC Form 4 filing.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and short-lived unless followed by additional disclosures.

Evidence & confidence

The filing is primary-source and time-stamped, but it does not indicate company-specific deterioration (no earnings, guidance, or regulatory action) and notes no 10b5-1 plan.

Market effects

Minimal; single-insider sale does not reset sector fundamentals.

None indicated.

None indicated.

Counterpoint

Director sales can be routine liquidity/portfolio rebalancing and may not reflect forward-looking views, especially without evidence of a broader pattern.

Key entities

  • CENTENE CORP

    Subject of the SEC Form 4 insider transaction disclosure.

  • Burdick Kenneth A

    Director who sold 80,000 shares in an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CNCMedAI 8/10

Centene Corp (CNC) (Q3 2026) Earnings Call Highlights: Raised Guidance and Medicare

Centene Corp (CNC) reported Q3 2026 earnings, raising guidance. Medicaid membership is expected to decline 8-9% YoY by 2026 end, with further attrition in 2027. Medicare Advantage membership may drop YoY in 2027. PDP pretax margin is forecasted to reset lower in 2027, initially at 2-3%. CEO Sarah London addressed market contraction expectations and cost-saving measures during the earnings call.

$CNCMedAI 8/10

What Centene (CNC) Said on Its Q3 Earnings Call

Centene (CNC) reported Q3 earnings, highlighting strong Medicare segment performance with a 93.8% HBR. The company raised its 2026 pre-tax margin forecast for PDP to mid-to-high 3% and expects Medicare Advantage break-even in 2026. Marketplace margins are improving, with a full-year 2026 pre-tax margin expected at the top of the 4.5%-5% range. Centene reduced debt to $15.0B and expects adjusted EPS growth in 2027.

$CNCHighAI 8/10

Centene (CNC) Q3 2026 Earnings Call Transcript

Centene (CNC) reported Q3 2026 earnings, highlighting a Medicaid HBR of 93.6, up 30 basis points from Q2. The company expects full-year Medicaid HBR of 93.5. Medicaid membership was in line with expectations, with a projected 8-9% year-end decline. Medicare Advantage and standalone Part D performed well, with Medicare Advantage on track for 2026 breakeven. Marketplace business is expected to produce a full-year pretax margin at the top of the 4.5% to 5.0% range.

$CNCMed

Centene Corporation Q3 2026 Earnings Call Summary

Centene Corporation reported Q3 2026 earnings, highlighting Medicare Advantage breakeven, Medicaid stability, and Marketplace margin recovery. The company reduced debt to $15.0 billion and expects 2027 adjusted EPS growth. Management plans to exit less profitable areas and optimize costs. Medicaid membership is declining, and Marketplace enrollment may contract in 2027. Non-recurring benefits added $0.50 per share in 2026.

$CNCMed

Centene progresses on profit recovery, drops 6,000 employees

Centene reported Q3 revenue of $50.6B, up 2% YoY, and narrowed losses to $71M. The company raised its 2026 earnings outlook due to Medicare Advantage cost reductions, now expecting to break even in the segment. Centene also announced layoffs and voluntary separations, reducing its workforce by 6,000 employees, which is expected to improve margins in 2027. The company's medical loss ratio was 92.7%, slightly better than expected.